{"transactions":[{"id":2191268,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":124790,"kind":"person","name":"Invus US Partners LLC","position":1,"cik":"0001839806","reported_name":"Invus US Partners LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107352,"kind":"organization","name":"Ulys, L.L.C.","position":2,"cik":"0001340098","reported_name":"Ulys, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T20:48:13.000Z","date":"2022-08-05","kind":"purchase","acquired":true,"shares":147390,"price":2.5,"value":368475.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the \"Issuer Common Stock\"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Invus US Partners LLC"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":5451204,"source":{"system":"sec-edgar","filing":"0000899243-22-028113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000089924322028113/doc4.xml","form_type":"4"}},{"id":2199349,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":124790,"kind":"person","name":"Invus US Partners LLC","position":1,"cik":"0001839806","reported_name":"Invus US Partners LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":107352,"kind":"organization","name":"Ulys, L.L.C.","position":2,"cik":"0001340098","reported_name":"Ulys, L.L.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41450,"kind":"person","name":"DEBBANE RAYMOND","position":3,"cik":"0001053890","reported_name":"DEBBANE RAYMOND","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:15:28.000Z","date":"2022-08-01","kind":"purchase","acquired":true,"shares":982600,"price":2.5,"value":2456500.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the \"Issuer Common Stock\") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are directly held by Invus US Partners LLC"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":5303814,"source":{"system":"sec-edgar","filing":"0000899243-22-027157","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000089924322027157/doc4.xml","form_type":"4"}}]}